The United States Food and Drug Administration (FDA) ensures that patients in the U.S. have access to safe and effective medical devices. The Division of Neurological and Physical Medicine Devices reviews medical technologies that interface with the nervous system. This article addresses how to navigate the FDA's regulatory landscape to successfully bring medical devices to patients.
Medical devices can have a significant impact on patients, caregivers, and the overall healthcare burden in the U.S., provided that safe and effective devices succeed in reaching the marketplace in a timely manner. Medical device technologies that interface with the central and peripheral nervous system (neurotechnologies) represent an emerging technology area of rapid development, growth, and promise. Neurotechnologies have the potential for substantial public health impact on mental or physical impairments due to the nature of conditions being treated, such as stroke, epilepsy, Parkinson's disease, Alzheimer's disease, traumatic brain injury (TBI), brain tumor, and pain. Neurotechnologies can span diagnostic and symptomatic treatments and may one day fulfill the promise of preventing disease progression. Within the Food and Drug Administration (FDA), the Center for Devices and Radiological Health (CDRH) is committed to increasing access to safe and effective medical devices for U.S. patients (Food and Drug Administration, 2015a) , and the Division of Neurological and Physical Medicine Devices (DNPMD) is the primary point of review at the FDA for regulatory submissions involving medical device neurotechnologies. This article presents an overview of medical device regulation, a summary of CDRH's review of neurotechnologies, and information on how sponsors (companies or principal investigators who submit marketing applications or clinical investigations to the FDA) can best engage CDRH.
Navigating the Regulatory Landscape for Medical Device Neurotechnologies CDRH determines the level of regulatory controls necessary for a medical device based upon its risks, classifying devices as class I, II, or III; regulatory control increases from class I to class III (Food and Drug Administration, 2014a). The level of regulatory control for an individual device is determined using a risk-based approach that involves evaluating the technology and the intended user as well as utilizing regulatory tools known as general and special controls. The device classification requirements are found in the There are a number of regulatory pathways available to bring medical devices to the market (Figure 1) . The specific pathway is determined by the degree of oversight needed in order to adequately control the risks of a device. For example, most class I devices (low risk), which require only general controls (Food and Drug Administration, 2014b), are exempt from submitting an application to the FDA; most class II devices (moderate risk) require premarket notification, also known as a 510(k) submission; and most class III devices (high risk) are subject to premarket approval (PMA). Class II devices cleared through the 510(k) pathway require a comparable, legally marketed class II device (i.e., a cleared predicate device) to which a sponsor can demonstrate ''substantial equivalence'' through a comparison of the intended use and technological characteristics of the devices (21 CFR, 2016, part 807; Food and Drug Administration, 2014c) . The largest review program at CDRH is the 510(k) pathway; CDRH receives several thousand 510(k) submissions each year, including neurotechnologies such as transcutaneous nerve stimulators, powered muscle stimulators, and aneurysm coils. Class III devices are most often approved through PMA applications, which typically require clinical data to demonstrate a reasonable assurance of safety and effectiveness (Food and Drug
